⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TARA News
Protara Therapeutics, Inc. Common Stock
Alport Syndrome Market to Grow at a Tremendous 47% CAGR Through 2036, Driven by Emerging Therapies and Expanding Clinical Pipeline | DelveInsight
prnewswire.com
ELOX
EVTC
NVS
TARA
Form 8-K
sec.gov
TARA
Form 8-K
sec.gov
TARA
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
globenewswire.com
TARA
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
globenewswire.com
TARA
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
globenewswire.com
TARA
Form 8-K
sec.gov
TARA
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
TARA
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
globenewswire.com
TARA
Form 8-K
sec.gov
PRTO
TARA